FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie
The FDA has accepted a supplemental application for SKYRIZI (Risankizumab) from AbbVie.
Company
AbbVie
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's acceptance of the supplemental application for SKYRIZI indicates a potential expansion of AbbVie's market presence in the IL-23 inhibitor segment. This could lead to intensified competition, particularly against established products like Tremfya and Benlysta.
Recommended action
Humanexa recommends Monitor: Monitoring is recommended to track the FDA's final decision and competitor responses, which will be crucial for strategic planning and market positioning.
Analysis
Monitor the timeline for the FDA's final decision and any subsequent market reactions from competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.